Reported 8 months ago
The impact of GLP-1 drugs like Novo Nordisk's Ozempic and Eli Lilly's Mounjaro on industries from food and beverage to health insurance is expected to take years to unfold. An analyst note from Bank of America set such expectations, causing stock drops in those sectors. Despite this, a Moody's Ratings report suggests a more optimistic outlook, stating that the impact will be gradual and result from decreased demand for products and services. Companies are already taking steps to mitigate the effects of these diabetes and weight loss drugs, with GLP-1s predicted to drive growth in the pharmaceutical sector while potentially negatively impacting other industries like medical devices, food and beverage, and health insurers in the long term.
Source: YAHOO